My laboratory studies the regulation and functional role of kinase signaling pathways in melanoma, which is the most aggressive form of skin cancer. We utilize a number of methods, including reverse phase protein arrays (RPPA), transcriptional profiling, and DNA sequencing, to allow for efficient and broad assessment of protein signaling networks. For clinical specimens, we use these and other methods to determine clinical and pathological correlates of different mutations and signaling pathway activation, including in patients treated with molecularly targeted therapies. In vitro, we use these methods to identify predictors of sensitivity and resistance to therapeutic agents. We also study the changes in protein and gene expression networks induced by different therapies to identify mechanisms of resistance, in order to develop rational, more effective combinatorial approaches. We also have a specific effort to understand the molecular biology of, and rational therapeutic approaches for, brain metastases.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.